#ASH22: J&J touts first PhII re­sults of next-gen mul­ti­ple myelo­ma an­ti­body

NEW OR­LEANS — A day af­ter sub­mit­ting its ap­pli­ca­tion to the FDA to use its drug tal­que­tam­ab for treat­ment of re­lapsed/re­frac­to­ry mul­ti­ple myelo­ma, John­son & John­son’s Janssen unit is out with the da­ta be­hind the treat­ment.

The com­pa­ny hopes the Phase II da­ta re­leased at the Amer­i­can So­ci­ety of Hema­tol­ogy med­ical con­fer­ence will back up an ac­cel­er­at­ed ap­proval for tal­que­tam­ab, sim­i­lar to the ac­cel­er­at­ed nod it re­ceived weeks ago for an­oth­er mul­ti­ple myelo­ma drug, Tec­vayli.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER